Determining antenatal medicine exposures in South African women: a comparison of three methods of ascertainment

Table 5 Inter-dataset agreement for combination therapies and selected ATC level 5 medications (Cohen’s kappa)

	EDR versus Clinician Record					EDR versus Self-Report					Clinician Record versus Self-Report
	kappa	95% CI	Strength	PABAK	95% CI	kappa	95% CI	Strength	PABAK	95% CI	kappa	95% CI	Strength	PABAK	95% CI
Any vitamins & supplements^a	0.03	0.01; 0.05	Slight	< 0.00		0.00	-0.03; 0.03	Poor	< 0.00		0.02	-0.05; 0.08	Slight	0.40	0.34; 0.45
Any ART	0.60	0.55; 0.65	Moderate	0.63	0.58; 0.68	0.77	0.73; 0.81	Substantial	0.78	0.74; 0.82	0.61	0.57;0.67	Substantial	0.63	0.59; 0.68
1st line^b	0.60	0.55; 0.66	Moderate	0.65	0.60; 0.69	0.76	0.72; 0.81	Substantial	0.77	0.73; 0.81	0.61	0.56;0.67	Substantial	0.64	0.59; 0.69
2nd line^b	0.68	0.51; 0.84	Substantial	0.98	0.96; 0.99	0.76	0.64; 0.88	Substantial	0.98	0.97; 0.99	0.62	0.45;0.78	Substantial	0.96	0.95; 0.98
STI syndromic treatment^c	0.06	-0.04; 0.15	Slight	0.84	0.81; 0.88	0.12	0.02; 0.21	Slight	0.80	0.76; 0.84	0.23	0.12; 0.43	Fair	0.82	0.80; 0.87
Benzathine penicillin (J01CE08)	None					None					0.04	-0.06; 0.15	Slight	0.93	0.90; 0.95
Treatment for TB^d	None			None		0.25	-0.15; 0.65	Fair	0.99	0.98; 1.00	None
INH (J04AC0) as TBPT	0.03	0.00; 0.06	Slight	0.66	0.62; 0.71	0.06	0.01; 0.10	Slight	0.67	0.62; 0.71	0.00	-0.00; 0.00	0.98	0.97; 0.99
Diabetes mellitus (A10)	0.26	-0.03; 0.56	Fair	0.98	0.96; 0.99	0.47	0.17; 0.76	Moderate	0.98	0.97; 0.99	< 0.00	-0.01; -0.00	Poor	0.99	0.97; 1.0
Oral^e	0.26	-0.03; 0.56	Fair	0.98	0.96; 0.99	0.47	0.17; 0.76	Moderate	0.98	0.97; 0.99	< 0.00	-0.01; -0.00	Poor	0.99	0.97; 1.0
A10A (insulins)	< 0.00		Poor	< 0.00		< 0.00		Poor	< 0.00		< 0.00	-0.00; 0.00	Poor	< 0.00

ACT Anatomical chemical therapeutic, ART Antiretroviral therapy, PABAK prevalence and bias-adjusted kappa, INH Isoniazid, NNRTI Non-nucleoside reverse transcriptase inhibitor NRTI Nucleoside reverse transcriptase inhibitor EDR Electronic dispensing record, PI Protease inhibitor, STI Sexually transmitted infection, TB Tuberculosis disease, TBTP TB preventive therapy, TCAM Traditional, complementary, alternative medicines
^a Excludes vitamin B6 which is prescribed exclusively with INH as TBPT
^b of the 450 women on ART; 1^st line NRTI backbone with NNRTI; 2.^nd line NRTI backbone with PI
^cmetronidazole/ceftraixone ± azithromycin ± amoxicillin
^d combination therapy of rifampcin + pyrazinamide + ethambutol + isoniazid
^e A10BA02 (metformin) or A10BB12 (glimepiride)

ISSN: 1471-2393